Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy .
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Durvalumab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 30 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Aug 2015 New trial record